Treatment Options to Reduce Disease Activity After Natalizumab: Paradoxical Effects of Corticosteroids

Silvia Rossi, Caterina Motta, Valeria Studer, Laura Boffa, Valentina De Chiara, Maura Castelli, Francesca Barbieri, Fabio Buttari, Fabrizia Monteleone, Giorgio Germani, Giulia Macchiarulo, Sagit Weiss, Diego Centonze

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: Natalizumab (NTZ) discontinuation leads to multiple sclerosis (MS) recurrence, but represents the only known strategy to limit the risk of progressive multifocal leukoencephalopathy (PML) in JCV seropositive patients. Here, we compared the clinical and imaging features of three groups of patients who discontinued NTZ treatment. Methods: We treated 25 patients with subcutaneous INFβ-1b (INF group), 40 patients with glatiramer acetate (GA group), and 40 patients with GA plus pulse steroid (GA+CS group). Results: Six of 25 patients (24%) of the INF group were relapse-free 6 months after NTZ suspension. In GA group, a significant higher proportion of patients (26 of 40 patients, 65%) were relapse-free (P <0.05). Far from improving the clinical effects of GA in post-NTZ setting, combination of GA+CS was associated with lower relapse-free rate than GA alone (40% vs. 65%, P = 0.04). Also on MRI parameters, combination of GA+CS was associated with worse outcome than GA alone, as 22 of 26 subjects (84.6%) had MRI evidence of disease activity 6 months after NTZ discontinuation. Conclusion: Corticosteroids should not be used in combination with GA to prevent post-NTZ disease recurrence.

Original languageEnglish
Pages (from-to)748-753
Number of pages6
JournalCNS Neuroscience and Therapeutics
Volume20
Issue number8
DOIs
Publication statusPublished - 2014

Keywords

  • Glatiramer acetate
  • Immunomodulation
  • JC virus
  • PML
  • Relapse

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Physiology (medical)
  • Psychiatry and Mental health
  • Pharmacology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Treatment Options to Reduce Disease Activity After Natalizumab: Paradoxical Effects of Corticosteroids'. Together they form a unique fingerprint.

Cite this